Connect with us

Science

JAXA shows the sub-surface samples it collected from asteroid Ryugu – Yahoo Tech

Published

 on


TipRanks

3 Stocks J.P. Morgan Says Are Ready to Rip Higher

Take a deep breath, get ready, the New Year is just around the corner, and while we’re all ready to celebrate – just on principle, because getting out of 2020 is reason enough for joy – let’s also take stock of where we are and where we’re headed.There’s a growing sense of optimism, engendered by the availability of COVID vaccines and the potential they give for a return to normal on Main Streets around the country. Finally, a chance that the lockdown and social distancing regimes truly are going to end, and in the near-term. There is a real chance that, by the end of a 2021, John Q. Public may be getting back on his feet.Combine that with Wall Street’s current ebullience, as stock markets trade at or near their all-time high levels, and we are looking at the prospect of a banner year. A return to grass roots normalcy will be great – but we also have the prospect of an overall rising market. Writing from JPMorgan, chief US equity strategist Dubravko Lakos-Bujas writes, “Equities are facing one of the best backdrops in years. Risks relating to global trade tensions, political uncertainty, and the pandemic, will be going away. At the same time, liquidity conditions remain extremely supportive, and there’s an extremely favorable interest-rate environment. That’s a Goldilocks environment for risky assets.”Lakos-Bujas doesn’t shy away from quantifying his optimism. He is predicting as much as 19% gains for the S&P 500, saying that the index will hit 4,000 in the early part of 2021 and reach as high as 4,400 in the later part of the year. Turning Lakos-Bujas’ outlook into concrete recommendations, JPM’s cadre of stock analysts are pounding the table on three stocks that look especially compelling. We ran the trio through TipRanks database to see what other Wall Street’s analysts have to say about.Sotera Health (SHC)Sotera Health occupies a unique niche in the healthcare industry, offering, through its subsidiaries, a range of safety-oriented support businesses for healthcare providers. These services include sterilization procedures, lab testing, and advisory services – and their importance is immediately clear. Sotera boasts over 5,800 healthcare provider customers in more than 50 countries around the world.While not a new company – two of its branches have been in business since the 1930s and 40s – Sotera is new to the stock markets, having held its IPO just this past November. The initial offering was considered successful, raising $1.2 billion on a sale of 53.6 million shares. Earlier this month, Sotera announced that it used much of the IPO capital to pay down $1.1 billion in existing debt. This included $341 million in a first lien term loan, plus the $770 million in aggregated principal on an issue of senior secured notes. The move allowed Sotera to increase its revolving credit facility to $347.5 million. That facility is currently undrawn.Among the bulls is JPM analyst Tycho Peterson who rates SHC an Overweight (i.e. Buy) along with a one-year price target of $35. This figure suggests a 31% upside from current levels. (To watch Peterson’s track record, click here)”SHC is uniquely positioned to benefit from healthy end-market growth and favorable pricing dynamics,” Peterson noted. “Given a diversified operating platform, sticky multi-year contracts, an efficient pricing strategy, significant barriers to entry and high regulatory oversight, we project ~9% sales growth, with higher utilization driving continued expansion [and] robust FCF supports ongoing de-leveraging, leaving us positive on both the near- and longer-term outlook.” The Wall Street analyst corps is firmly behind Peterson on this one – in fact, the 7 recent reviews are unanimous Buys, making the analyst consensus a Strong Buy. SHC is currently trading for $26.75, and its $32.50 average price target implies an upside of 21.5% by the end of 2021. (See SHC stock analysis on TipRanks)Myovant Sciences (MYOV)Let’s stick with the health care industry, and look at Myovant Sciences. This clinical research biopharma company focuses on major issues of reproductive system disease in both men and women. Specifically, Myovant is working to develop treatments for uterine fibroids, endometriosis, and prostate cancer.Myovant’s pipeline currently features Relugolix as a treatment for fibroids and endometriosis. The drug is in Phase 3 trial for the latter, and has had its NDA submitted for the former. Also in the pipeline, and related to reproductive health, is MVT-602, a new drug designed to enhance egg maturation and aid in vitro fertilization.In addition, Myovant has announced this month that Relugolix has been FDA approved – under the brand name Orgovyx – as a treatment for advanced prostate cancer. The drug is the first, and currently only, Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for the disease. Orgovyx is expected to enter the market in January 2021.Analyst Eric Joseph, in his note on this stock for JPM, describes how he is impressed by Relugolix “based on the clinical and commercial potential of lead asset relugolix for the treatment of endometriosis and uterine fibroids, as well as in men for the treatment of advanced prostate cancer.”The analyst added, “In women’s health, we believe the totality of phase 3 data to date de-risks the likelihood of relugolix approval in the US for uterine fibroids and endometriosis – commercial opportunities that are underreflected at current levels. Further, we see an attractive commercial setup for relugolix in the treatment of advanced prostate cancer as an oral LHRH alternative with a differentiated CV risk profile.”These comments support Joseph’s Overweight (i.e. Buy) rating on MYOV, and his $30 price target implies a 31% upside for the next 12 months. (To watch Joseph’s track record, click here)Overall, the Strong Buy analyst consensus rating on Myovant comes from 5 reviews, and the breakdown is clearly for the bulls: 4 to 1 in favor Buy versus Hold. The stock’s $22.80 share price and $36.40 average price target give a robust upside potential of ~59%. (See MYOV stock analysis on TipRanks)Metropolitan Bank Holding (MCB)For the third stock, we’ll change lanes from health care to finance, where Metropolitan Bank Holding operates – through its subsidiary, Metropolitan Commercial Bank – as a full-service bank for business, entrepreneurial, and personal customers in the mid-market segment. The bank’s services include business lending, cash management, deposits, electronic banking, personal checking, and prepaid cards. In a year that has been difficult for most of us, MCB has managed to post steadily increasing revenues and solid earnings. The bank’s top line has increased from $33 million in Q1 to $36 million in Q3. EPS was stronger, at $1.27 per share, up 30% year-over-year. The gains come as the bank gives forward guidance of $153.9 million in total revenues for next year, which – if met – will reflect a 22% gain over 2020.While MCB’s financial performance has shown steady gains, the share appreciation has not followed suit. The stock has only partially recouped losses taken last winter at the height of the corona crisis, and is currently down 26% this year.Watching the New York banking scene from JPM, analyst Steven Alexopoulos notes general difficulties in the commercial real estate loan sector – an important part of MCB’s portfolio – due to the ongoing pandemic issues. In this environment, he sees Metropolitan Bank as the right choice.“We’re not as bearish as most on the outlook for New York real estate. Having witnessed many cycles in NYC, the time to buy has been when the herd is running in the other direction. In past cycles, MCB has been an outperformer on credit metrics in regards to its loan portfolio relative to our coverage group,” Alexopoulos noted.Alexopoulos goes on to explain another key strength in MCB’s loan portfolio: “In a low interest rate environment, MCB stands better positioned than peers to withstand NIM headwinds with 59% of MCB’s loans being fixed rate and 67% of the remaining floating rate loans have floors to protect from lower short-term rates…” To this end, Alexopoulos rates MCB an Overweight (i.e. Buy) along with a $50 price target. Should the target be met, investors could pocket gains of 43% over the next year. (To watch Alexopoulos’ track record, click here)Some stocks fly under the radar, and MCB is one of those. Alexopoulos’ is the only recent analyst review of this company, and it is decidedly positive. (See MCB stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Let’s block ads! (Why?)



Source link

Continue Reading

Science

Rumbling meteor lights up Norway, a bit possibly landing near Oslo – Euronews

Published

 on


By Nora Buli

OSLO -An “unusually large meteor” briefly lit up southern Norway on Sunday, creating a spectacular sound and light display as it rumbled across the sky, and a bit of it may have hit Earth, possibly not far from the capital, Oslo, experts said.

There were no immediate reports of injuries or damage.

Reports of sightings started arriving around 1 a.m. with the phenomena being seen as far north as Trondheim.

A web camera in Holmestrand, south of Oslo, captured a fireball falling from the sky and erupting into a bright flash lighting up a marina.

The Norwegian Meteor network was analysing video footage and other data on Sunday to try to pinpoint the meteor’s origin and destination.

Preliminary data suggested a meteorite may have hit Earth in a large wooded area, called Finnemarka, just 60 km (40 miles) west of the capital, Oslo, the network said.

“This was crazy,” the network’s Morten Bilet, who saw and heard the meteor, told Reuters.

By Sunday afternoon no debris had been found and given the “demanding” location, one could take “some 10 years” searching for possible meteorites, Bilet said.

The meteor travelled at 15-20 km per second and lit up the night sky for about five to six seconds, Bilet said. The summer sky was dark, with the days starting to get shorter from the end of June.

Some eyewitnesses also said they felt a stronger wind blow with the event also causing a pressure wave, Bilet said.

“What we had last night was a large rock travelling likely from between Mars and Jupiter, which is our asteroid belt. And when that whizzes in, it creates a rumble, light and great excitement among us (experts) and maybe some fear among others,” Bilet said.

There were no reports of damage or people being particularly frightened, Bilet said, adding that for those nearest it was likely more of a “spooky” event.

A meteor that exploded over the central Russia near the city of Chelyabinsk in 2013 rained fireballs over a vast area and caused a shock wave that smashed windows, damaged buildings and injured 1,200 people.

Adblock test (Why?)



Source link

Continue Reading

Science

Seaspan plan to expand North Van dry dock ruffles its waterfront neighbours – Vancouver Sun

Published

 on


Seaspan’s plans to consolidate its ship repair business at Vancouver Drydock is running into opposition from its residential neighbours.

Article content

Seaspan Shipbuilding is outgrowing its operations on the North Shore, but the company’s plans to expand its companion Vancouver Drydock is colliding with concerns of the residential neighbourhood that has grown up around the century-old industrial waterfront.

Advertisement

Article content

Building new ships for the Canadian Coast Guard and Royal Canadian Navy was absorbing Seaspan’s capacity to repair ships at its main shipyard at the end of Pemberton Avenue, said company spokeswoman Kris Neely.

Neely said the company has been thinking about expanding for awhile, as part of a vision to create a “multi generational business.”

“As part of that, we’re consolidating our repair and maintenance services out of Vancouver Drydock and then being able to focus on shipbuilding efforts at our Vancouver Shipyard.”

Their plan is to push Seaspan’s existing dry dock facilities on the Lower Lonsdale waterfront 40 metres further into Burrard Inlet, then ask the Port of Vancouver to extend its water lot lease 40 metres to the west in order to add three smaller dry docks.

Advertisement

Article content

Seaspan submitted an application for a review of the plan to the port in April. That federal authority deemed the application complete on June 21, opening up a public comment period. That included virtual public meetings July 13 and 15, and ends July 30.

Many of the comments from residents of condo towers that face the proposed expansion have expressed opposition to allowing Seaspan’s migration west when it has space to the east of its existing docks that is already within its lease.

It isn’t just a matter of views being blocked by new facilities jutting out in front of condos, said resident Al Parsons. Residents are concerned about the impact of additional noise and pollution, including tug boats operating in the waters in front of Shipyard Commons, the bustling commercial district and public space with its waterfront trail and a playground.

Advertisement

Article content

“We knew Seaspan was our neighbour when we moved in,” Parsons said. “What we didn’t know was that they were going to continue to move westward and, I think, impose themselves on the (waterfront) Spirit Trail.

“It has walkers, joggers, cyclists, there’s a playground that was built for kids, which is going to be right beside this expansion.”

Parsons said residents aren’t opposed to the idea of expansion and support an initiative that Seaspan says would create 100 jobs, but don’t like there wasn’t any consultation before the company submitted its application.

And they are pushing back against a possible westward expansion, unless Seaspan proves it cannot expand east within their existing lease.

The City of North Vancouver is working on a response to Seaspan’s proposal, but would like to see the public comment period extended and all resident and business concerns taken into consideration.

Advertisement

Article content

“I understand the concerns and share many of them,” Mayor Linda Buchanan said in a statement. “This project will bring more family-supporting jobs to the community, but the quality of life of residents needs to be a priority as well.”

Neely said Seaspan did look at other options for this expansion, but siting the new dry docks on the east side of its operations would block water access to a fabrication shop on the site that builds components for new vessels at Vancouver Shipyards.

However, Parsons argued that the east side is perhaps more inconvenient for Seaspan, which would be free to use the east side of its property for other purposes if it were granted a westward expansion.

“I know the water lot is deemed industrial but, frankly, Seaspan is pushing too hard on this neighbourhood that a lot of people contribute tax dollars to support annually.”

depenner@postmedia.com

twitter.com/derrickpenner

Advertisement

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Adblock test (Why?)



Source link

Continue Reading

Science

NASA selects SpaceX for mission to Jupiter moon Europa – Jakarta Post

Published

 on


NASA on Friday said it had selected SpaceX to launch a planned voyage to Jupiter’s icy moon Europa, a huge win for Elon Musk’s company as it sets its sights deeper into the solar system.

The Europa Clipper mission will launch in October 2024 on a Falcon Heavy rocket from the Kennedy Space Center in Florida, with the total contract worth $178 million.

The mission was previously supposed to take off on NASA’s own Space Launch System (SLS) rocket, which has been plagued by delays and cost overruns, with critics calling it a “jobs program” for the state of Alabama where much of the development work is taking place.

While SLS isn’t yet operational, Falcon Heavy has deployed on both commercial and government missions since its maiden flight in 2018 when it carried Musk’s own Tesla Roadster into space.

It generates more than five million pounds of thrust (22 million Newtons) at liftoff, equal to approximately eighteen 747 aircraft.

The Europa clipper orbiter will make about 40 to 50 close passes over Europa to determine whether the icy moon could harbor conditions suitable for life.

Its payload will include cameras and spectrometers to produce high-resolution images and compositional maps of the surface and atmosphere, as well as radar to penetrate the ice layer to search for liquid water below.

<!–

Your premium period will expire in 0 day(s)

close x

Subscribe to get unlimited access Get 50% off now

–>

Adblock test (Why?)



Source link

Continue Reading

Trending